Evidence map›Paper›PMID 20599959›Full record

ArticleExperimental eye research2010

AAV serotype influences gene transfer in corneal stroma in vivo.

Ajay Sharma, Jonathan C K Tovey, Arkasubhra Ghosh, Rajiv R Mohan

Open access · greenAbstract read
In one paragraph

Article in Experimental eye research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 50 citations in OpenAlex.

  1. Long-Term Tolerability and Safety of AAV5-Id3 Gene Therapy to Eyes.Translational vision science & technology · 2026
    Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Gene Therapy in the Anterior Eye Segment.Current gene therapy · 2022
    Review
  7. Article
  8. Article
  9. Novel insights into gene therapy in the cornea.Experimental eye research · 2021
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Ajay SharmaHarry S Truman Memorial Veterans' Hospital, Columbia, MO 65201, USA.
Jonathan C K Tovey
Arkasubhra Ghosh
Rajiv R Mohan
Harry S. Truman Memorial Veterans' Hospital · USInstitute of Molecular and Cell Biology · SGMissouri College · USUniversity of Missouri · US

Funding

Gene Therapy in the CorneaR01EY017294 · NEI · UNIVERSITY OF MISSOURI-COLUMBIA · PI MOHAN, RAJIV RAVINDRA · 2007 to 2018
$4.3M
BLRD VA I01 BX000357NEI NIH HHS R01 EY017294NEI NIH HHS R01EY17294NEI NIH HHS R01EY17294S2
6 · The paper itself

Abstract

This study evaluated the cellular tropism and relative transduction efficiency of three AAV serotypes, AAV6, AAV8 and AAV9, for corneal gene delivery using mouse cornea in vivo and donor human cornea ex vivo. The AAV6, AAV8 and AAV9 serotypes having AAV2 plasmid encoding for alkaline phosphatase (AP) gene were generated by transfecting HEK 293 cell line with pHelper, pARAP4 and pRep/Cap plasmids. Viral vectors (10(9) vg/microl) were topically applied onto mouse cornea in vivo and human cornea ex vivo after removing the epithelium. Human corneas were processed for transgene delivery at day 5 after viral vector application. Mouse corneas were harvested at 4, 14 and 30 days after vector application for AP staining. Transduction efficiency was calculated by quantifying pixels of AP-stained area using Image J software and also confirmed by functional AP enzyme activity in the corneal lysates. Cellular toxicity of the three AAV serotypes was tested with TUNEL assay. Inflammatory response was detected by immunostaining for CD11b and F4/80. All three AAV serotypes successfully transduced mouse and human corneas. The order of transduction efficiency was AAV9 > AAV8 > AAV6. The transduction efficiency of AAV9 was 1.1-1.4 fold higher (p > 0.05) as compared to AAV8 and 3.5-5.5 fold higher (p < 0.01) as compared to AAV6. The level of transgene expression for all the three serotypes was greater at 14 days compared to 4 days and this high level of transgene expression was maintained up to the tested time point of 30 days. Corneas exposed to any of the three AAV serotypes did not show significant TUNEL positive cells or any inflammatory response as tested by CD11b or F4/80 staining suggesting that tested AAV serotypes do not induce cell death or inflammation and are safe for corneal gene therapy.

Indexed as

Genetic VectorsTransduction, GeneticAlkaline PhosphataseAnimalsAntigens, DifferentiationCD11b AntigenCorneal StromaDependovirusFemaleFluorescent Antibody Technique, IndirectGene Expression Regulation, EnzymologicHumansIn Situ Nick-End LabelingMiceMice, Inbred C57BLPlasmidsAlkaline PhosphataseAntigens, DifferentiationCD11b Antigenmonocyte-macrophage differentiation antigen

Identifiers

PMID20599959
PMCPMC2926174
OpenAlexW1989136633

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.